Vonoprazan + Lansoprazole

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Erosive Esophagitis

Conditions

Erosive Esophagitis

Trial Timeline

Oct 28, 2019 → Aug 24, 2021

About Vonoprazan + Lansoprazole

Vonoprazan + Lansoprazole is a phase 3 stage product being developed by Phathom Pharmaceuticals for Erosive Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04124926. Target conditions include Erosive Esophagitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04729101Phase 1Completed
NCT04124926Phase 3Completed

Competing Products

20 competing products in Erosive Esophagitis

See all competitors
ProductCompanyStageHype Score
YH1885L(Revaprazan) + Esomeprazole 20mg + placeboYuhanPhase 2
52
E3810 + E3810 + PlaceboEisaiPhase 3
77
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
77
Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenoneEisaiApproved
85
ABT-981 + Placebo for ABT-981AbbViePhase 2
52
OmeprazoleAstraZenecaPhase 3
77
Esomeprazole + LansoprazoleAstraZenecaApproved
85
Nexium 20mg + Nexium 10mgAstraZenecaPhase 3
77
OmeprazoleAstraZenecaPhase 3
77
AZD0865AstraZenecaPhase 2
52
Esomeprazole + LansoprazoleAstraZenecaApproved
85
Esomeprazole + EsomeprazoleAstraZenecaApproved
85
AZD0865AstraZenecaPhase 2
52
esomeprazole magnesium (oral medication)AstraZenecaApproved
85
Alendronate Effervescent Oral TabletAmgenPhase 2
51
Omeprazole/sodium bicarbonateBausch HealthApproved
80
VonoprazanPhathom PharmaceuticalsPhase 1
28
Vonoprazan + PlaceboPhathom PharmaceuticalsPhase 2
47
VonoprazanPhathom PharmaceuticalsPre-clinical
18
Vonoprazan + PlaceboPhathom PharmaceuticalsPhase 3
72